DX 103
Alternative Names: DX-103; Mydriatic MicroRxLatest Information Update: 12 Jun 2018
At a glance
- Originator Eyenovia
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Mydriasis